<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2461">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635241</url>
  </required_header>
  <id_info>
    <org_study_id>INHALE-HEP meta-trial</org_study_id>
    <nct_id>NCT04635241</nct_id>
  </id_info>
  <brief_title>Inhaled Heparin for Hospitalised COVID-19 Patients</brief_title>
  <acronym>INHALE-HEP</acronym>
  <official_title>INHALEd Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 Meta-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australian National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica San Camilo, Argentina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australian National University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This meta-trial is a prospective collaborative individual participant data meta-analysis of&#xD;
      randomised controlled trials and early phase studies. Individual studies will be conducted in&#xD;
      multiple countries, including Australia, the UK, Argentina, Brazil and Egypt.&#xD;
&#xD;
      Adult patients admitted to the hospital with confirmed SARS-CoV-2 infection, who do not&#xD;
      require immediate mechanical ventilation, will be randomised to inhaled nebulised heparin or&#xD;
      standard care for up to 21 days or until the patient has no respiratory symptoms. All studies&#xD;
      will collect a minimum core dataset. The primary outcome for the meta-trial is the proportion&#xD;
      of patients who receive invasive mechanical ventilation censored at day 28. Individual&#xD;
      studies may have specific outcome measures in addition to the core set.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation rate</measure>
    <time_frame>Day 28</time_frame>
    <description>Proportion of patients requiring invasive mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO ordinal scale COVID19</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of patients showing 1 or 2 point worsening on the ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>Day 7</time_frame>
    <description>Daily ratio of partial pressure of oxygen to FiO2 (PaO2/FiO2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">712</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Inhaled heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled nebulised unfractionated heparin in addition to standard care Dose 25,000 IU every 6 hours for up to 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin</intervention_name>
    <description>Inhaled nebulised 6 hourly</description>
    <arm_group_label>Inhaled heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to hospital with COVID-19&#xD;
&#xD;
          -  No immediate requirement for mechanical ventilation (points 3-5 on the WHO ordinal&#xD;
             scale)&#xD;
&#xD;
          -  Age equal to or greater than 18&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Known allergy to Heparin&#xD;
&#xD;
          -  Participant in another clinical trial that is not approved for joint enrollment.&#xD;
&#xD;
          -  APTT&gt; 120 seconds, not due to anticoagulant therapy.&#xD;
&#xD;
          -  Platelet count &lt;20 x 109 per L&#xD;
&#xD;
          -  Lung bleeding.&#xD;
&#xD;
          -  Uncontrolled bleeding&#xD;
&#xD;
          -  Advanced neurological impairment&#xD;
&#xD;
          -  Advanced oncological disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank MP van Haren, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Australian National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank MP van Haren, MD, PhD</last_name>
    <phone>+61467051809</phone>
    <email>frank.vanharen@anu.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Camilo Clinic</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia B Vilaseca, PhD</last_name>
      <email>avilaseca@clinicasancamilo.org.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>15th May hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek I Ismail</last_name>
      <phone>00201001467166</phone>
      <email>drtarek.anesth@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>van Haren FMP, Page C, Laffey JG, Artigas A, Camprubi-Rimblas M, Nunes Q, Smith R, Shute J, Carroll M, Tree J, Carroll M, Singh D, Wilkinson T, Dixon B. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care. 2020 Jul 22;24(1):454. doi: 10.1186/s13054-020-03148-2. Review.</citation>
    <PMID>32698853</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Australian National University</investigator_affiliation>
    <investigator_full_name>Frank van Haren</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

